Jangsoon Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jangsoon Lee has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Naoto T. Ueno
University of Hawaiʻi Cancer Center Inflammatory Breast Cancer Clinic and Research Program, Honolulu, USA
35 shared publications - Dileep Reddy Rampa
Preclinical Core, Cancer Biology Program, University of Hawai‘i Cancer Center, Honolulu, Hawaii
17 shared publications - Kyoji Tsuchikama
Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, Texas
15 shared publications - Debu Tripathy
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
12 shared publications - Jennifer A. Maynard
McKetta Department of Chemical Engineering, The University of Texas at Austin, Austin, Texas, USA
11 shared publications - Troy Pearson
Section of Translational Breast Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
11 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
Supplementary Table 5 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
Supplementary Table 5 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
Supplementary Table 2 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
Supplementary Table 2 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
Supplementary Table 3 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
Supplementary Table 3 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-8 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
Including supplementary figures and legends, and supplementary references.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-8 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
Including supplementary figures and legends, and supplementary references.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
Purpose:Antibody–drug conjugates (ADC) have transformed the treatment of breast cancer. FDA-approved ADC such as trastuzumab deruxtecan (T-DXd), sacituzumab govitecan (SG), and datopotamab deruxtecan (Dato-DXd) have demonstrated clinical benefit; however, drug resistance will almost inevitably emerge in the metastatic setting, and there is no established strategy for selecting subsequent ADC after disease progression following the first exposure to the ADC. This study aimed to define mechanisms of acquired resistance and evaluate rational sequencing approaches.Experimental Design:We generated breast cancer cell lines resistant to T-DXd (TDXd-R) and SG (SG-R). We assessed antigen expression, internalization, and resistance pathways, including efflux transporter activity. To identify therapeutic strategies, we tested the efficacy of ADC carrying non–topoisomerase I (Topo1) payloads in in vitro and in vivo models.Results:Resistance in both TDXd-R and SG-R models was primarily mediated by payload-specific factors, notably upregulation of efflux transporters, rather than loss of antigen expression. Switching to ADC with mechanistically different payloads, including microtubule inhibitors, restored antitumor activity in vitro and in vivo.Conclusions:Cross-resistance to sequential ADC is primarily driven by shared payload mechanisms rather than loss of the target. Our data also suggest that the clinical benefit of sequential Topo1-based ADC may be reduced following disease progression on a Topo1-based ADC, likely due to these shared resistance pathways. Importantly, switching to ADC with non–cross-resistant payload classes may offer a more effective approach to guide ADC sequencing in patients with metastatic breast cancer, supporting payload diversification as a clinically actionable strategy.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
Purpose:Antibody–drug conjugates (ADC) have transformed the treatment of breast cancer. FDA-approved ADC such as trastuzumab deruxtecan (T-DXd), sacituzumab govitecan (SG), and datopotamab deruxtecan (Dato-DXd) have demonstrated clinical benefit; however, drug resistance will almost inevitably emerge in the metastatic setting, and there is no established strategy for selecting subsequent ADC after disease progression following the first exposure to the ADC. This study aimed to define mechanisms of acquired resistance and evaluate rational sequencing approaches.Experimental Design:We generated breast cancer cell lines resistant to T-DXd (TDXd-R) and SG (SG-R). We assessed antigen expression, internalization, and resistance pathways, including efflux transporter activity. To identify therapeutic strategies, we tested the efficacy of ADC carrying non–topoisomerase I (Topo1) payloads in in vitro and in vivo models.Results:Resistance in both TDXd-R and SG-R models was primarily mediated by payload-specific factors, notably upregulation of efflux transporters, rather than loss of antigen expression. Switching to ADC with mechanistically different payloads, including microtubule inhibitors, restored antitumor activity in vitro and in vivo.Conclusions:Cross-resistance to sequential ADC is primarily driven by shared payload mechanisms rather than loss of the target. Our data also suggest that the clinical benefit of sequential Topo1-based ADC may be reduced following disease progression on a Topo1-based ADC, likely due to these shared resistance pathways. Importantly, switching to ADC with non–cross-resistant payload classes may offer a more effective approach to guide ADC sequencing in patients with metastatic breast cancer, supporting payload diversification as a clinically actionable strategy.
- Open Access
- 17 April 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (6) , 111476
Antibodies blocking PlGF or VEGF interactions with the NRP1 receptor mediate antiproliferative effects
- 17 April 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (6) , 111476
Open AccessAntibodies blocking PlGF or VEGF interactions with the NRP1 receptor mediate antiproliferative effects
- Open Access
- 15 April 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 135 (1) , 33-47
ATR inhibition potentiates the antitumor efficacy of HER3-DXd in HER3-positive/HR-positive breast cancer by increasing DNA damage
Endocrine resistance remains a major challenge in hormone receptor-positive (HR+) breast cancer (BC), where up to 70% of tumours overexpress HER3, a receptor associated with poor prognosis and therapeutic resistance. HER3-DXd (patritumab deruxtecan) is currently under clinical investigation for HER3-expressing metastatic BC. However, strategies to further enhance its efficacy, particularly in endocrine therapy-resistant settings, are urgently needed. We hypothesised that targeting ATR, a key regulator of DNA damage repair (DDR), potentiates HER3-DXd in HER3+/HR+ BC, including tamoxifen-resistant (TMR) disease. Synergistic partners for HER3-DXd were identified by whole-genome RNAi screening. Treatments' effects on cell cycle, DNA damage, and protein expression were analysed using flow cytometry, comet assay, and Western blotting, respectively. Treatments' antitumor efficacy was assessed using xenograft mouse models. TCGA and CPTAC databases were analysed for clinical relevance. HER3-DXd inhibited growth in both parental and TMR MCF7 and T47D cells. Compared to monotherapies, combining HER3-DXd with an ATR inhibitor enhanced DNA damage, sub-G1 arrest, apoptosis, downregulation of DDR and cell cycle regulatory proteins, and tumour growth inhibition. TCGA and CPTAC analyses confirmed high HER3 expression and correlation of ATR, CHEK1, and TOP1 gene expression with poor prognosis in HR+ BC. Combining HER3-DXd with an ATR inhibitor could benefit HER3+/HR+ BC patients with both endocrine-sensitive and -resistant diseases.
- 15 April 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 135 (1) , 33-47
Open AccessATR inhibition potentiates the antitumor efficacy of HER3-DXd in HER3-positive/HR-positive breast cancer by increasing DNA damage
Endocrine resistance remains a major challenge in hormone receptor-positive (HR+) breast cancer (BC), where up to 70% of tumours overexpress HER3, a receptor associated with poor prognosis and therapeutic resistance. HER3-DXd (patritumab deruxtecan) is currently under clinical investigation for HER3-expressing metastatic BC. However, strategies to further enhance its efficacy, particularly in endocrine therapy-resistant settings, are urgently needed. We hypothesised that targeting ATR, a key regulator of DNA damage repair (DDR), potentiates HER3-DXd in HER3+/HR+ BC, including tamoxifen-resistant (TMR) disease. Synergistic partners for HER3-DXd were identified by whole-genome RNAi screening. Treatments' effects on cell cycle, DNA damage, and protein expression were analysed using flow cytometry, comet assay, and Western blotting, respectively. Treatments' antitumor efficacy was assessed using xenograft mouse models. TCGA and CPTAC databases were analysed for clinical relevance. HER3-DXd inhibited growth in both parental and TMR MCF7 and T47D cells. Compared to monotherapies, combining HER3-DXd with an ATR inhibitor enhanced DNA damage, sub-G1 arrest, apoptosis, downregulation of DDR and cell cycle regulatory proteins, and tumour growth inhibition. TCGA and CPTAC analyses confirmed high HER3 expression and correlation of ATR, CHEK1, and TOP1 gene expression with poor prognosis in HR+ BC. Combining HER3-DXd with an ATR inhibitor could benefit HER3+/HR+ BC patients with both endocrine-sensitive and -resistant diseases.
- Open Access
- 24 March 2026
- Published by Wiley in Advanced Science
- Vol. 13 (35) , e15498
Understanding and Overcoming Antibody‐Drug Conjugate Resistance: Biological Mechanisms and Emerging Analytical Frameworks in Breast Cancer
Antibody‐drug conjugates (ADCs) have revolutionized the treatment landscape of breast cancer by combining the precision of monoclonal antibodies with the potency of cytotoxic agents. Despite the clinical success of ADCs—with 4 FDA‐approved agents to date, and 15 for the entire cancer landscape—their therapeutic durability is frequently undermined by acquired resistance. Rather than arising solely from tumor‐intrinsic alterations, ADC resistance reflects a multi‐layered process shaped by dynamic interactions among cancer cells and the tumor microenvironment (TME), with activation of adaptive signaling networks. For example, stromal architecture, vascular heterogeneity, and immune modulation intersect with clonal evolution, phenotypic plasticity, and pathway reprogramming, thereby constraining ADC delivery and activity. Cutting‐edge technologies such as spatial omics, single‐cell profiling, functional genomics, and patient‐derived models are redefining how these resistance mechanisms are mapped and understood in situ. Building on these insights, emerging therapeutic strategies aim to overcome resistance through mechanism‐guided interventions, including next‐generation ADC designs, co‐targeting of compensatory signaling pathways, and biomarker‐informed therapeutic strategies. Together, these integrated biological and technological perspectives provide a framework for developing more durable and precisely tailored ADC‐based therapies in breast cancer.
- 24 March 2026
- Published by Wiley in Advanced Science
- Vol. 13 (35) , e15498
Open AccessUnderstanding and Overcoming Antibody‐Drug Conjugate Resistance: Biological Mechanisms and Emerging Analytical Frameworks in Breast Cancer
Antibody‐drug conjugates (ADCs) have revolutionized the treatment landscape of breast cancer by combining the precision of monoclonal antibodies with the potency of cytotoxic agents. Despite the clinical success of ADCs—with 4 FDA‐approved agents to date, and 15 for the entire cancer landscape—their therapeutic durability is frequently undermined by acquired resistance. Rather than arising solely from tumor‐intrinsic alterations, ADC resistance reflects a multi‐layered process shaped by dynamic interactions among cancer cells and the tumor microenvironment (TME), with activation of adaptive signaling networks. For example, stromal architecture, vascular heterogeneity, and immune modulation intersect with clonal evolution, phenotypic plasticity, and pathway reprogramming, thereby constraining ADC delivery and activity. Cutting‐edge technologies such as spatial omics, single‐cell profiling, functional genomics, and patient‐derived models are redefining how these resistance mechanisms are mapped and understood in situ. Building on these insights, emerging therapeutic strategies aim to overcome resistance through mechanism‐guided interventions, including next‐generation ADC designs, co‐targeting of compensatory signaling pathways, and biomarker‐informed therapeutic strategies. Together, these integrated biological and technological perspectives provide a framework for developing more durable and precisely tailored ADC‐based therapies in breast cancer.